Role of mirabegron in the management of overactive bladder: a knowledge, attitude, and practice survey among Indian healthcare professionals

Madhu Sudan Agrawal; Sanjay  Pandey; Prem Kumar; Vikram Sahu; Dinesh Patil

doi:10.18203/2320-6012.ijrms20241963

Authors

Madhu Sudan Agrawal Department of Urology, Pushpanjali Hospital and Research Centre, Agra, Uttar Pradesh, India
Sanjay Pandey Department of Andrology and Reconstructive Urology, Kokilaben Dhirubhai Ambani Hospital, Mumbai, Maharashtra, India
Prem Kumar Ranchi Urology Centre, Ranchi, Jharkhand, India
Vikram Sahu Department of Medical Services, Alembic Pharmaceuticals, Mumbai, Maharashtra, India
Dinesh Patil Department of Medical Services, Alembic Pharmaceuticals, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20241963

Keywords:

Overactive bladder, Mirabegron, Antimuscarinic, KAP survey, β-3 agonist

Abstract

Background: Overactive bladder (OAB) is identified by urinary urgency, with or without urgency urinary incontinence, typically accompanied by increased daytime urinary frequency and nocturia, in the absence of proven infection or other evident pathology.

Methods: A cross-sectional, observational, questionnaire-based knowledge, attitude, and practice (KAP) survey was conducted across India from January 2022 to July 2023 to understand OAB therapy through 14 multiple–choice questions containing questionnaire shared with 1, 029 healthcare professionals (HCPs), including urologists, surgeons, nephrologists, and consulting physicians.

Results: The HCPs see 10-20% of patients daily in clinical practice, wherein 5-10% are females. Patients usually consult general practitioners first and then other specialists. Although anticholinergics are commonly used in the management of OAB, HCPs reported that side effects (57%) and the high cost of therapy (43%) were mainly responsible for discontinuing anticholinergics. Mirabegron was preferred by 67% of HCPs in the treatment of these patients. Mirabegron is also preferred as a first-line treatment by all HCPs in this survey. It is prescribed for 6-12 months, has a response rate of >75% in clinical practice, and offers a more favourable side-effect profile compared to anticholinergics. In cases where patients do not respond to anticholinergics or experience treatment failure, a combination therapy of mirabegron and solifenacin is preferred.

Conclusions: The survey highlights the use of mirabegron as a first-line treatment for OAB, its better side-effect profile, and its role in combination therapy with solifenacin for patients unresponsive to anticholinergics, ultimately improving the quality of life of patients.

Metrics

Metrics Loading ...

References

Scarneciu I, Lupu S, Bratu OG, Teodorescu A, Maxim LS, Brinza A, et al. Overactive bladder: A review and update. Exp Ther Med. 2021;22(6):1444.

Yang CF, Huang CY, Wang SY, Chang SR. Prevalence of and Associated Factors for Overactive Bladder Subtypes in Middle-Aged Women: A Cross-Sectional Study. Medicina (Kaunas). 2022;58(3):383.

Pal M, Bandyopadhyay S, Roy A. Overactive bladder symptom score – translation and linguistic validation in Bengali. J Family Med Prim Care. 2022;11:79-83.

Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive Bladder Syndrome: Evaluation and Management. Curr Urol. 2018;11(3):117-25.

Nitti VW, Patel A, Karram M. Diagnosis and management of overactive bladder: A review. J Obstet Gynaecol Res. 2021;47(5):1654-65.

Mandpe P, Prabhakar BA. Pathophysiology, mechanism and management of overactive bladder syndrome-A review. Int J Pharm Pharm Sci. 2018;10:1-3.

Araklitis G, Baines G, da Silva AS, Robinson D, Cardozo L. Recent advances in managing overactive bladder. F1000Research. 2020;9.

Papagiannis D, Malli F, Raptis DG, Papathanasiou IV, Fradelos EC, Daniil Z, et al. Assessment of knowledge, attitudes, and practices towards new coronavirus (SARS-CoV-2) of health care professionals in Greece before the outbreak period. Int J Env Res Public Health. 2020;17(14):4925.

Khadke J, Dhupkar A. Prevalence of overactive bladder syndrome among adult females having stress urinary incontinence and urge urinary incontinence using overactive bladder syndrome questionnaire. Int J Health Sci Res. 2023;13(3):55-68.

O'Kane M, Robinson D, Cardozo L, Wagg A, Abrams P. Mirabegron in the Management of Overactive Bladder Syndrome. Int J Womens Health. 2022;14:1337-50.

Dmochowski RR, Newman DK, Rovner ES, Zillioux J, Malik RD, Ackerman AL. Patient and Clinician Challenges with Anticholinergic Step Therapy in the Treatment of Overactive Bladder: A Narrative Review. Adv Ther. 2023;40(11):4741-57.

Chancellor MB, Migliaccio-Walle K, Bramley TJ, Chaudhari SL, Corbell C, Globe D. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clin Ther. 2013;35(11):1744-51.

Khullar V, Cambronero J, Angulo JC, Wooning M, Blauwet MB, Dorrepaal C, et al. Efficacy of Mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. BMC Urol. 2013;13:45.

Nambiar AK, Arlandis S, Bø K, Cobussen-Boekhorst H, Costantini E, de Heide M, et al. European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence. Eur Urol. 2022;82(1):49-59.

Shin JH, Choo MS. Effectiveness and persistence of mirabegron as a first-line treatment in patients with overactive bladder in real-life practice. Low Urin Tract Symptoms. 2019;11(3):151-7.

Kuo HC. How to choose appropriate medication for overactive bladder: Findings from the largest integrated clinical trial database analysis of mirabegron studies. Tzu Chi Med J. 2020;34(1):23-8.

Allison SJ, Gibson W. Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience. Ther Adv Urol. 2018;10(12):411-9.

Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015;67(3):577-88.

Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, et al. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol. 2016;70(1):136-45.

MacDiarmid S, Al-Shukri S, Barkin J, Fianu-Jonasson A, Grise P, Herschorn S, et al. Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected]. J Urol. 2016;196(3):809-18.

Corcos J, Przydacz M, Campeau L, Gray G, Hickling D, Honeine C, et al. CUA guideline on adult overactive bladder. Can Urol Assoc J. 2017;11(5):E142-73.